Gilead (GILD) announced that the FDA has accepted its new drug application submissions for lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of HIV as pre-exposure prophylaxis. The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act target action date of June 19.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Arcus Biosciences price target lowered to $25 from $36 at Morgan Stanley
- Deutsche upgrades Gilead to Buy on ability to offset patent cliffs
- Arcus Biosciences retains rights to casdatifan
- Gilead upgraded to Buy from Hold at Deutsche Bank
- Buy Recommendation for Gilead Sciences: Promising Outlook with Seladelpar Approval and Robust Drug Portfolio